TSE:AUP - Aurinia Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
C$6.98 -0.17 (-2.38 %)
(As of 08/19/2018 05:41 AM ET)
Previous CloseC$6.98
Today's RangeC$6.89 - C$7.14
52-Week RangeC$5.68 - C$9.50
Volume22,300 shs
Average Volume38,283 shs
Market CapitalizationC$596.22 million
P/E RatioN/A
Dividend YieldN/A
Beta3.34
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. It has a sales agreement with Cantor Fitzgerald & Co.; and a manufacturing collaboration and services agreement with Lonza Ltd. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.

Receive AUP News and Ratings via Email

Sign-up to receive the latest news and ratings for AUP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange TSE
Industry Technical & System Software
Sub-IndustryN/A
SectorComputer and Technology
SymbolTSE:AUP
CUSIPN/A
Phone+1-250-7084272

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-45,241.38%
Return on Equity-30.41%
Return on Assets-25.82%

Miscellaneous

EmployeesN/A
Outstanding Shares84,200,000
Market CapC$596.22 million

Aurinia Pharmaceuticals (TSE:AUP) Frequently Asked Questions

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "AUP."

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc (TSE:AUP) issued its quarterly earnings results on Thursday, August, 9th. The company reported ($0.25) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.04. The firm earned $0.04 million during the quarter, compared to the consensus estimate of $0.07 million. Aurinia Pharmaceuticals had a negative net margin of 45,241.38% and a negative return on equity of 30.41%. View Aurinia Pharmaceuticals' Earnings History.

When is Aurinia Pharmaceuticals' next earnings date?

Aurinia Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 13th 2018. View Earnings Estimates for Aurinia Pharmaceuticals.

What is the consensus analysts' recommendation for Aurinia Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aurinia Pharmaceuticals.

Who are some of Aurinia Pharmaceuticals' key competitors?

Who are Aurinia Pharmaceuticals' key executives?

Aurinia Pharmaceuticals' management team includes the folowing people:
  • Dr. Richard M. Glickman, Founder, Chairman, Pres & CEO (Age 60)
  • Mr. Michael R. Martin, Co-Founder & COO
  • Mr. Dennis Bourgeault C.A., CFO & Sec.
  • Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.
  • Dr. Neil Solomons M.D., Chief Medical Officer

Has Aurinia Pharmaceuticals been receiving favorable news coverage?

Media coverage about AUP stock has trended somewhat positive on Sunday, according to Accern Sentiment. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Aurinia Pharmaceuticals earned a news impact score of 0.02 on Accern's scale. They also assigned news stories about the company an impact score of 46.12 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for Aurinia Pharmaceuticals.

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Aurinia Pharmaceuticals' stock price today?

One share of AUP stock can currently be purchased for approximately C$6.98.

How big of a company is Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals has a market capitalization of C$596.22 million.

How can I contact Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals' mailing address is 1203-4464 Markham St, VICTORIA, BC V8Z 7X8, Canada. The company can be reached via phone at +1-250-7084272.


MarketBeat Community Rating for Aurinia Pharmaceuticals (TSE AUP)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  135 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  228
MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe AUP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2018 by MarketBeat.com Staff

Featured Article: Dividend

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.